top of page

Re-Imagining Tumor Visualization

CANCER SURGERY IN A NEW LIGHT

Tumor-targeted agents to help surgeons realize the full potential of minimally invasive and robotic-assisted cancer surgery

Vergent Bioscience is a clinical-stage biotechnology company that is helping surgeons realize the full potential of minimally invasive and robotic-assisted surgery by improving the visibility of tumors. Vergent’s lead compound, abenacianine for injection (VGT-309), is a tumor-targeted fluorescent imaging agent intentionally designed to enable surgeons to see previously undetected or difficult-to-find tumors during surgery in real time, so they can ensure all tumor tissue is removed during surgery. The company is first evaluating VGT-309 in lung cancer, with the potential to expand its application to a wide range of solid tumors.

Containers

Technology

Highly differentiated agent unlocking the potential of real-time tumor visualization

Research Focus

Optimizing surgery as a first-line treatment for solid tumors

About Us

Committed to making cancer surgery more successful for surgeons and patients

A Strong Foundation to Transform Care

Bringing together an innovative investigational imaging agent, a commitment to rigorous science, and a world-class leadership team, Vergent Bioscience is positioned to become the global leader in intraoperative tumor visualization.

Vergent-Bio-Patient-Image-1322494780_edited.jpg

Improving the first line of cancer treatment

Vergent is working with surgeons to increase the accessibility and therapeutic potential of cancer surgery for patients with solid tumors.

bottom of page